Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Avantis International Small Cap Value ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Avantis International Small Cap Value ETF trades at $110.38. Which is the better fit depends on your goals.
| ACAD | AVDV | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Sector/Thematic |
52-Week High | $29.41 | $110.40 |
52-Week Low | $20.06 | $83.89 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
AVDV trades at $110.51, up 0.96% today, with a bullish technical outlook from moving averages but caution from oscillators like the 6-day RSI at 87.64 indicating overbought conditions. Recent news highlights strong 2026 performance, with international small-cap value strategies gaining attention. The stock shows support near $108-$109 and resistance at $110.
The outlook remains positive due to momentum in international small-cap value, though overbought signals and reliance on commodity sectors pose risks. Investors should weigh the ETF's diversification benefits against potential volatility from global economic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →
